Eddie04
Well-known member
Survodutide & Cagrilintide: What We Know, What We Don't, and How People Are Using Them
Hi everyone — I've seen more questions lately about survodutide ("Survo") and cagrilintide ("Cagri")], especially from people who have already used semaglutide, tirzepatide, or even retatrutide and are looking for something different.
This post is meant to organize what we currently understand from trials, mechanistic data, and real-world discussion. As always, this is educational discussion — not medical advice.
--------------------------------------------------
PART 1: QUICK MECHANISM OVERVIEW
--------------------------------------------------
Before comparing drugs, it's helpful to understand their targets.
Semaglutide → GLP-1 receptor agonist
Tirzepatide → GLP-1 + GIP receptor agonist
Retatrutide → GLP-1 + GIP + glucagon receptor agonist ("triple agonist")
Survodutide → GLP-1 + glucagon receptor agonist (dual agonist)
Cagrilintide → Amylin receptor agonist (NOT GLP-1)
So we are dealing with different hormonal systems:
This matters because side effect profiles and appetite suppression patterns differ.
--------------------------------------------------
PART 2: SURVODUTIDE (GLP-1 + GLUCAGON)
--------------------------------------------------
Why are people interested in Survo?
Common reasons I see:
Weight Loss Data (So Far)
In trials, weight loss appears:
It is not currently showing the dramatic 20%+ reductions seen with high-dose tirzepatide or retatrutide in trials.
What About Heart Rate?
Glucagon receptor activation can increase energy expenditure — but also potentially heart rate.
Interestingly, early discussions suggest survodutide may not produce the same resting heart rate increase observed with triple agonists. That said, we do not have massive real-world datasets yet.
If someone is specifically concerned about:
Survodutide is sometimes viewed as a middle ground between tirzepatide and reta.
Food Noise & Appetite
Reports are limited. Compared to tirzepatide:
This is a major limitation — we simply don't have large community experience yet.
--------------------------------------------------
PART 3: CAGRILINTIDE (AMYLIN AGONIST)
--------------------------------------------------
Cagrilintide is a different category entirely.
It mimics amylin, a hormone co-secreted with insulin. Amylin:
In trials, cagrilintide combined with semaglutide has shown very strong weight reduction.
Anecdotally, Cagri is often described as:
But responses vary significantly.
--------------------------------------------------
PART 4: TOLERANCE & LOW RESPONDERS
--------------------------------------------------
One theme we repeatedly see: some individuals lose significant weight early, then plateau despite dose increases.
Common patterns:
There are documented "low responders" in trials.
Important points:
Some individuals experiment with:
Escalating to very high doses (well above studied ranges) is discussed in some circles, but safety data is limited and caution is essential.
--------------------------------------------------
PART 5: SURVO VS RETA
--------------------------------------------------
A common comparison.
Retatrutide
Survodutide
If someone:
--------------------------------------------------
PART 6: KI VALUES & RECEPTOR AFFINITY
--------------------------------------------------
Occasionally you'll see discussions about "Ki values." These represent binding affinity.
Lower Ki = stronger binding to the receptor.
However:
Ki values are interesting mechanistically, but they are not a practical dosing guide.
--------------------------------------------------
PART 7: DOSING CONSIDERATIONS (GENERAL DISCUSSION)
--------------------------------------------------
Not prescribing — just summarizing common approaches seen in trials and discussion.
Survodutide:
Cagrilintide:
Many users report that starting low with Cagri is critical due to intensity of satiety.
--------------------------------------------------
PART 8: SUBJECTIVE VS OBJECTIVE OUTCOMES
--------------------------------------------------
One of the most important reminders:
Feeling hungry ≠ not losing weight.
Conversely:
Feeling appetite suppression ≠ guaranteed fat loss.
Track:
There are documented cases of:
Hormonal systems are complex.
--------------------------------------------------
PART 9: WHO MIGHT CONSIDER WHAT?
--------------------------------------------------
Someone early in treatment
→ Start with established agents (sema or tirz). No reason to jump to newer compounds.
Someone stalled on tirz 15 mg
→ Options people explore:
Someone very sensitive to HR increases
→ Survo may be worth monitoring vs triple agonist.
Someone whose main issue is food noise
→ Cagrilintide often discussed as particularly effective.
--------------------------------------------------
PART 10: REALITY CHECK
--------------------------------------------------
We are still early in this therapeutic era.
Retatrutide and survodutide are not widely available as approved medications yet in many regions.
Long-term safety data:
Be cautious about:
--------------------------------------------------
FINAL THOUGHTS
--------------------------------------------------
Survodutide appears to be:
Cagrilintide appears to be:
The most important variables remain:
If others here have real-world experience with Survo or Cagri — especially after plateau on tirz — please share details (dose, duration, HR changes, weight change, side effects).
The more structured data we collect as a community, the more useful these discussions become.
Looking forward to hearing everyone's experiences.
Hi everyone — I've seen more questions lately about survodutide ("Survo") and cagrilintide ("Cagri")], especially from people who have already used semaglutide, tirzepatide, or even retatrutide and are looking for something different.
This post is meant to organize what we currently understand from trials, mechanistic data, and real-world discussion. As always, this is educational discussion — not medical advice.
--------------------------------------------------
PART 1: QUICK MECHANISM OVERVIEW
--------------------------------------------------
Before comparing drugs, it's helpful to understand their targets.
Semaglutide → GLP-1 receptor agonist
Tirzepatide → GLP-1 + GIP receptor agonist
Retatrutide → GLP-1 + GIP + glucagon receptor agonist ("triple agonist")
Survodutide → GLP-1 + glucagon receptor agonist (dual agonist)
Cagrilintide → Amylin receptor agonist (NOT GLP-1)
So we are dealing with different hormonal systems:
- GLP-1 → satiety, slowed gastric emptying, insulin secretion
- GIP → insulinotropic effects, possibly adipose modulation
- Glucagon receptor → increases energy expenditure, can increase heart rate
- Amylin → satiety signaling, meal termination, reduced food noise
This matters because side effect profiles and appetite suppression patterns differ.
--------------------------------------------------
PART 2: SURVODUTIDE (GLP-1 + GLUCAGON)
--------------------------------------------------
Why are people interested in Survo?
Common reasons I see:
- Curiosity about dual GLP-1/glucagon effects
- Concern about resting heart rate increases seen with triple agonists like reta
- Desire for something "different" after tolerance to tirzepatide
- Comparable per-dose cost in some settings
Weight Loss Data (So Far)
In trials, weight loss appears:
- Generally similar to semaglutide
- Less than tirzepatide at higher doses
- Dose-dependent (highest studied dose around ~4.8 mg weekly)
It is not currently showing the dramatic 20%+ reductions seen with high-dose tirzepatide or retatrutide in trials.
What About Heart Rate?
Glucagon receptor activation can increase energy expenditure — but also potentially heart rate.
Interestingly, early discussions suggest survodutide may not produce the same resting heart rate increase observed with triple agonists. That said, we do not have massive real-world datasets yet.
If someone is specifically concerned about:
- Elevated resting HR on retatrutide
- Sympathetic activation
- Cardiac sensitivity
Survodutide is sometimes viewed as a middle ground between tirzepatide and reta.
Food Noise & Appetite
Reports are limited. Compared to tirzepatide:
- Satiety appears present but not overwhelmingly stronger
- Less anecdotal discussion overall
- Fewer community reports, which makes interpretation difficult
This is a major limitation — we simply don't have large community experience yet.
--------------------------------------------------
PART 3: CAGRILINTIDE (AMYLIN AGONIST)
--------------------------------------------------
Cagrilintide is a different category entirely.
It mimics amylin, a hormone co-secreted with insulin. Amylin:
- Promotes satiety
- Reduces meal size
- Slows gastric emptying
- Reduces food reward signaling
In trials, cagrilintide combined with semaglutide has shown very strong weight reduction.
Anecdotally, Cagri is often described as:
- Extremely powerful for food noise suppression
- Causing early fullness even with small intake
- Sometimes "too strong" at higher doses
But responses vary significantly.
--------------------------------------------------
PART 4: TOLERANCE & LOW RESPONDERS
--------------------------------------------------
One theme we repeatedly see: some individuals lose significant weight early, then plateau despite dose increases.
Common patterns:
- Strong response up to 7.5-10 mg tirzepatide
- Minimal additional effect at 12.5-15 mg
- Food noise returning late in dosing interval
There are documented "low responders" in trials.
Important points:
- Appetite perception is subjective
- Weight change is objective
- Tolerance can develop
- Dose spacing adjustments sometimes help
Some individuals experiment with:
- Shortening interval (e.g., every 5-6 days)
- Adding cagrilintide to existing GLP-1 therapy
- Switching pathways (e.g., moving to a glucagon-containing agonist)
Escalating to very high doses (well above studied ranges) is discussed in some circles, but safety data is limited and caution is essential.
--------------------------------------------------
PART 5: SURVO VS RETA
--------------------------------------------------
A common comparison.
Retatrutide
- Triple agonist
- Very high weight loss potential in trials
- More resting HR increase reported
- Strong metabolic effects
Survodutide
- Dual agonist (GLP-1 + glucagon)
- Moderate-to-strong weight loss
- Less community data
- Possibly milder cardiovascular stimulation
If someone:
- Needs >20% body weight reduction → Reta or high-dose tirz likely more powerful
- Is sensitive to heart rate changes → Survo may be appealing
- Values established data → Tirzepatide still has strongest real-world track record
--------------------------------------------------
PART 6: KI VALUES & RECEPTOR AFFINITY
--------------------------------------------------
Occasionally you'll see discussions about "Ki values." These represent binding affinity.
Lower Ki = stronger binding to the receptor.
However:
- Higher binding affinity does NOT automatically mean better weight loss
- Clinical effect depends on receptor activation pattern
- Pharmacokinetics matter more than raw binding strength
Ki values are interesting mechanistically, but they are not a practical dosing guide.
--------------------------------------------------
PART 7: DOSING CONSIDERATIONS (GENERAL DISCUSSION)
--------------------------------------------------
Not prescribing — just summarizing common approaches seen in trials and discussion.
Survodutide:
- Studied in escalating weekly doses
- Highest studied around ~4.8 mg
- GI side effects similar to GLP-1 agents
Cagrilintide:
- Often started very low (microgram range)
- Titrated slowly
- Can produce strong fullness even at modest doses
Many users report that starting low with Cagri is critical due to intensity of satiety.
--------------------------------------------------
PART 8: SUBJECTIVE VS OBJECTIVE OUTCOMES
--------------------------------------------------
One of the most important reminders:
Feeling hungry ≠ not losing weight.
Conversely:
Feeling appetite suppression ≠ guaranteed fat loss.
Track:
- Weekly average weight
- Waist measurement
- Energy levels
- Resting heart rate
- Blood pressure
- Lipids if possible
There are documented cases of:
- Cholesterol improving without weight loss
- Weight loss without dramatic appetite change
- Strong appetite suppression with minimal scale change
Hormonal systems are complex.
--------------------------------------------------
PART 9: WHO MIGHT CONSIDER WHAT?
--------------------------------------------------
Someone early in treatment
→ Start with established agents (sema or tirz). No reason to jump to newer compounds.
Someone stalled on tirz 15 mg
→ Options people explore:
- Interval adjustment
- Adding amylin pathway (cagrilintide)
- Switching to triple agonist
- Switching to GLP-1 + glucagon (survo)
Someone very sensitive to HR increases
→ Survo may be worth monitoring vs triple agonist.
Someone whose main issue is food noise
→ Cagrilintide often discussed as particularly effective.
--------------------------------------------------
PART 10: REALITY CHECK
--------------------------------------------------
We are still early in this therapeutic era.
Retatrutide and survodutide are not widely available as approved medications yet in many regions.
Long-term safety data:
- Limited beyond trial populations
- Limited at very high doses
- Limited for combination stacking outside formal studies
Be cautious about:
- Rapid titration
- Extreme dose escalation
- Combining multiple agents without clear rationale
--------------------------------------------------
FINAL THOUGHTS
--------------------------------------------------
Survodutide appears to be:
- A promising dual agonist
- Likely comparable to semaglutide in magnitude
- Potentially less intense than triple agonists
- Under-discussed due to limited user base
Cagrilintide appears to be:
- A powerful appetite regulator
- Particularly strong for food noise
- Best used cautiously with slow titration
- Potentially synergistic with GLP-1 agents
The most important variables remain:
- Individual biology
- Tolerance patterns
- Cardiovascular response
- Metabolic health markers
If others here have real-world experience with Survo or Cagri — especially after plateau on tirz — please share details (dose, duration, HR changes, weight change, side effects).
The more structured data we collect as a community, the more useful these discussions become.
Looking forward to hearing everyone's experiences.
